ReviewCell death & disease2025
Long non-coding RNAs in cancer glycolysis and metabolism: mechanisms and translational opportunities.
Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Changes in the metabolism of axillary lymph node cells as a predictor of regional metastasis in breast cancer.World journal of experimental medicine · 2026Article
- Review
- Long non-coding RNAs in the crosstalk between diabetes and colorectal cancer: molecular mechanisms and endocrine pathways.Frontiers in molecular biosciences · 2026Review
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
- Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) have emerged as critical regulators of cancer metabolism, particularly in the reprogramming of glycolysis that supports tumor growth and survival. Once considered non-functional genomic "noise", lncRNAs influence metabolic adaptation by modulating glycolytic enzymes, transcription factors, and signaling pathways, while also shaping the tumor microenvironment through immune and stromal interactions. In addition, lncRNA-encoded micropeptides provide an extra layer of metabolic control, underscoring their functional diversity. These features indicate lncRNAs as promising diagnostic biomarkers and therapeutic targets, particularly in the context of personalized cancer treatments. RNA-based therapies demonstrate preclinical efficacy in targeting glycolytic lncRNA and reversing drug resistances. Nonetheless, challenges remain, including delivery specificity, off-target effects, and limited clinical validation. Advances in single-cell multi-omics, spatial transcriptomics, and artificial intelligence may offer new avenues to overcome these challenges. Collectively, lncRNAs represent both mechanistic drivers of glycolysis and promising targets for innovative diagnostic and therapeutic strategies in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.